FOROSA PILLS COATED 70MG
FOROSA PILLS COATED 70MG - 12 tabs
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
Mechanism of action
FOROSE is a non-hormonal specific inhibitor of osteoclastic bone resorption that inhibits osteoclast activity. It stimulates osteogenesis, restores a positive balance between resorption and restoration of bone, increases bone mineral density (regulates phosphorus-calcium metabolism), promotes the formation of bone tissue with a normal histological structure.
Indications and usage
- treatment of osteoporosis in postmenopausal women, incl. to reduce the risk of spinal compression and hip fractures;
- treatment of osteoporosis in men in order to prevent fractures;
- treatment of osteoporosis caused by prolonged use of corticosteroids.
- strictures or achalasia of the esophagus and other conditions leading to slower movement of food through the esophagus;
- the inability of the patient to stand or sit for 30 minutes;
- renal failure severe (CC less than 35 ml / min);
- severe violations of mineral metabolism;
- lactation period (breastfeeding);
- children's age (efficiency and safety of use are not established);
- Hypersensitivity to alendronate or other components of the drug.
WITH caution the drug should be prescribed to patients with gastrointestinal diseases (dysphagia, gastritis, duodenitis, peptic ulcer in the acute stage, active Gastrointestinal bleeding or surgery on the upper GI in history), hypovitaminosis D.
Dosage and administration
Tablets should be taken in the morning, no later than 30 minutes before the first meal, drink or other drug, with a full glass of plain water (at least 200 ml). pills can not be chewed. You should not take a horizontal position of the body, at least for 30 minutes after taking the drug. You can not take the drug at bedtime or until the morning rise from the bed.
The recommended dose is 70 mg (1 tablet) 1 time per week.
For elderly patients and patients with moderate renal impairment (CC more than 35 ml / min) dose adjustment is not required.
Gastrointestinal: abdominal pain, dyspeptic disorders (constipation or diarrhea, flatulence, nausea, vomiting), dysphagia, heartburn, esophagitis, dystonia of the stomach, ulceration of the mucous membrane of the mouth, throat, esophagus, stomach and duodenum, melena.
Nervous system: headaches, irritability.
Musculoskeletal system: osteonecrosis of the jaw was rarely observed in the treatment of bisphosphonates.
On the part of the organ of vision: uveitis, scleritis.
Allergic reactions: hypersensitivity reactions (including hyperemia of the skin, urticaria, angioedema).
Other: photosensitization, asymptomatic transient hypocalcemia and hypophosphatemia.
The simultaneous use of Calcium preparations (including nutritional supplements) and antacids worsens the absorption of alendronate. In this regard, it is recommended to take other drugs not earlier than 30 minutes after taking the drug. Foroza®.
NSAIDs (including acetylsalicylic acid) can increase the side effects of alendronic acid on the part of the gastrointestinal tract.
Despite the fact that there were no special studies on drug interactions, the use of alendronate in clinical studies with a large number of widely used drugs was not accompanied by the development of a clinically significant interaction.
Symptoms: abdominal pain, dyspeptic disorders, dysphagia, heartburn, esophagitis, gastritis; hypocalcemia and hypophosphatemia may develop.
Treatment symptomatic. The use of milk and antacid preparations for binding alendronate is shown. Due to the risk of damage to the esophagus, one should not induce vomiting, the patient should be in an upright position.
At a temperature not higher than 25 ° С.